{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:07:29Z","timestamp":1764997649164,"version":"3.32.0"},"reference-count":33,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,12,13]]},"DOI":"10.1248\/bpb.b24-00490","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:13:22Z","timestamp":1734041602000},"page":"2050-2057","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological Properties of JTE-151; A Novel Orally Available ROR\u03b3 Antagonist That Suppresses Th17 Cell-Related Responses &lt;i&gt;in Vitro&lt;\/i&gt; and &lt;i&gt;in Vivo&lt;\/i&gt;"],"prefix":"10.1248","volume":"47","author":[{"given":"Kojo","family":"Arita","sequence":"first","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Tao","sequence":"additional","affiliation":[{"name":"Orphagen Pharmaceuticals, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Crowe","sequence":"additional","affiliation":[{"name":"Orphagen Pharmaceuticals, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Thacher","sequence":"additional","affiliation":[{"name":"Orphagen Pharmaceuticals, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Otake","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ebihara","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Katsuda","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsuyoshi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. <i>Blood<\/i>, <b>112<\/b>, 1557\u20131569 (2008).","DOI":"10.1182\/blood-2008-05-078154"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Luckheeram RV, Zhou R, Verma AD, Xia B. CD4<sup>+<\/sup> T cells: differentiation and functions. <i>Clin. Dev. Immunol.<\/i>, <b>2012<\/b>, 925135 (2012).","DOI":"10.1155\/2012\/925135"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Saravia J, Chapman NM, Chi H. Helper T cell differentiation. <i>Cell. Mol. Immunol.<\/i>, <b>16<\/b>, 634\u2013643 (2019).","DOI":"10.1038\/s41423-019-0220-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1\/Th2 polarization. <i>Immunol. Today<\/i>, <b>21<\/b>, 479\u2013483 (2000).","DOI":"10.1016\/S0167-5699(00)01712-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. <i>J. Immunol.<\/i>, <b>155<\/b>, 1151\u20131164 (1995).","DOI":"10.4049\/jimmunol.155.3.1151"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4<sup>+<\/sup> effector T cells develop <i>via<\/i> a lineage distinct from the T helper type 1 and 2 lineages. <i>Nat. Immunol.<\/i>, <b>6<\/b>, 1123\u20131132 (2005).","DOI":"10.1038\/ni1254"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. <i>Nat. Immunol.<\/i>, <b>6<\/b>, 1133\u20131141 (2005).","DOI":"10.1038\/ni1261"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. <i>Immunity<\/i>, <b>30<\/b>, 324\u2013335 (2009).","DOI":"10.1016\/j.immuni.2009.03.003"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. <i>Nature<\/i>, <b>441<\/b>, 235\u2013238 (2006).","DOI":"10.1038\/nature04753"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhang W, Liu X, Zhu Y, Liu X, Gu Y, Dai X, Li B. Transcriptional and posttranslational regulation of Th17\/Treg balance in health and disease. <i>Eur. J. Immunol.<\/i>, <b>51<\/b>, 2137\u20132150 (2021).","DOI":"10.1002\/eji.202048794"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. <i>J. Exp. Med.<\/i>, <b>201<\/b>, 233\u2013240 (2005).","DOI":"10.1084\/jem.20041257"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ. TGF-\u03b2 and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. <i>Nat. Immunol.<\/i>, <b>8<\/b>, 1390\u20131397 (2007).","DOI":"10.1038\/ni1539"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O\u2019Shea JJ, Cua DJ. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells <i>in vivo.<\/i> <i>Nat. Immunol.<\/i>, <b>10<\/b>, 314\u2013324 (2009).","DOI":"10.1038\/ni.1698"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A. Role of Th17 cells in human autoimmune arthritis. <i>Arthritis Rheum.<\/i>, <b>62<\/b>, 2876\u20132885 (2010).","DOI":"10.1002\/art.27622"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. <i>J. Invest. Dermatol.<\/i>, <b>128<\/b>, 1207\u20131211 (2008).","DOI":"10.1038\/sj.jid.5701213"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R, Zhang H. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. <i>Inflamm. Res.<\/i>, <b>63<\/b>, 943\u2013950 (2014).","DOI":"10.1007\/s00011-014-0768-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mills KHG. IL-17 and IL-17-producing cells in protection <i>versus<\/i> pathology. <i>Nat. Rev. Immunol.<\/i>, <b>23<\/b>, 38\u201354 (2023).","DOI":"10.1038\/s41577-022-00746-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Jetten AM. Retionid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. <i>Nucl. Recept. Signal.<\/i>, <b>7<\/b>, nrs.07003 (2009).","DOI":"10.1621\/nrs.07003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17<sup>+<\/sup> T helper cells. <i>Cell<\/i>, <b>126<\/b>, 1121\u20131133 (2006).","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sun N, Xie Q, Dang Y, Wang Y. Agonist lock touched and untouched retinoid acid receptor-related orphan receptor-\u03b3t (ROR\u03b3t) inverse agonists: Classification based on the molecular mechanisms of action. <i>J. Med. Chem.<\/i>, <b>64<\/b>, 10519\u201310536 (2021).","DOI":"10.1021\/acs.jmedchem.0c02178"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yamamoto K. Discovery of nuclear receptor ligands and elucidation of their mechanisms of action. <i>Chem. Pharm. Bull.<\/i>, <b>67<\/b>, 609\u2013619 (2019).","DOI":"10.1248\/cpb.c19-00131"},{"key":"22","unstructured":"22) Maeba T, Hirata K, Kotoku M, <i>et al.<\/i> Discovery and SAR of JTE-151: a novel ROR\u03b3 inhibitor for clinical development. <i>J. Med. Chem.<\/i>, <b>67<\/b>, 952\u2013970 (2024)."},{"key":"23","unstructured":"23) Thacher S, Li X, Babine R, Tse BUS. Patent 8389739 (2013)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Noguchi M, Nomura A, Murase K, <i>et al.<\/i> Ternary complex of human ROR\u03b3 ligand-binding domain, inverse agonist and SMRT peptide shows a unique mechanism of corepressor recruitment. <i>Genes Cells<\/i>, <b>22<\/b>, 535\u2013551 (2017).","DOI":"10.1111\/gtc.12494"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Uesato N, Inagaki K, Miyagawa N, Kitagawa Y, Kakefuda R, Matsuo Y, Yamaguchi T, Hata T, Ikegashira K, Matsushita M. JTE-952 suppresses bone destruction in collagen-induced arthritis in mice by inhibiting colony stimulating factor 1 receptor. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1884\u20131892 (2020).","DOI":"10.1248\/bpb.b20-00517"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. <i>J. Immunol.<\/i>, <b>171<\/b>, 6173\u20136177 (2003).","DOI":"10.4049\/jimmunol.171.11.6173"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Rutz S, Eidenschenk C, Kiefer JR, Ouyang W. Post-translational regulation of ROR\u03b3t -A therapeutic target for the modulation of interleukin-17-mediated responses in autoimmune diseases. <i>Cytokine Growth Factor Rev.<\/i>, <b>30<\/b>, 1\u201317 (2016).","DOI":"10.1016\/j.cytogfr.2016.07.004"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kono M, Ochida A, Oda T, <i>et al.<\/i> Discovery of [<i>cis<\/i>-3-({(5R)-5-[(7-fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl}carbonyl)cyclobutyl]acetic acid (TAK-828F) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor \u03b3t inverse agonist. <i>J. Med. Chem.<\/i>, <b>61<\/b>, 2973\u20132988 (2018).","DOI":"10.1021\/acs.jmedchem.8b00061"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) J\u00e4ger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. <i>J. Immunol.<\/i>, <b>183<\/b>, 7169\u20137177 (2009).","DOI":"10.4049\/jimmunol.0901906"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. <i>Cell. Immunol.<\/i>, <b>237<\/b>, 123\u2013130 (2005).","DOI":"10.1016\/j.cellimm.2005.11.002"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein RA, Cua DJ. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. <i>J. Clin. Invest.<\/i>, <b>116<\/b>, 1317\u20131326 (2006).","DOI":"10.1172\/JCI25308"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Corneth OBJ, Mus AMC, Asmawidjaja PS, Klein Wolterink RG, van Nimwegen M, Brem MD, Hofman Y, Hendriks RW, Lubberts E. Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. <i>Arthritis Rheumatol.<\/i>, <b>66<\/b>, 340\u2013349 (2014).","DOI":"10.1002\/art.38229"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. <i>Arthritis Rheum.<\/i>, <b>58<\/b>, 3710\u20133719 (2008).","DOI":"10.1002\/art.24126"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/12\/47_b24-00490\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T03:39:03Z","timestamp":1734752343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/12\/47_b24-00490\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00490","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"b24-00490"}}